top of page
  • Recruiting
    • Sep 19, 2022

NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Myeloma

NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Teclistamab Expanded Access

NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients


The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.

 

Sponsor

Janssen Pharmaceutical

 

ClinicalTrials.gov Identifier: NCT05463939

Official Title: Teclistamab US Expanded Access Treatment Protocol for Patients With Relapsed or Refractory Multiple Myeloma

First Posted : July 19, 2022

Click here to see details on ClinicalTrials.gov

 

JNJ 64007957 - Teclistamab